Advancing Our Robust and High Potential Pipeline

20% (50M+) of US adults experience chronic pain and about 8% have high impact chronic pain which significantly disrupts life and work activities. Opioids, while effective, are highly addictive and only provide short-term relief. Approximately 25% of patients misuse opioids prescribed for chronic pain, resulting in over 70,000 overdose deaths per year. To combat this growing epidemic, Psy is developing a first-in-class non-addictive analgesic for effective pain management without the risk of misuse. Further, the program’s novel chemical formulation has potential to transition patients from opioid to non-opioid pain treatment. PSY-05001 recently completed Lead Optimization and has entered IND-enabling studies.

Generalized Anxiety Disorder (GAD):
6.8M+ US adults suffer from Generalized Anxiety Disorder (GAD), which manifests in physical and emotional symptoms that are highly disruptive to a person’s life.* Existing treatments are limited by suboptimal efficacy and undesirable side effects. Psy is pursuing a first-in-class GAD treatment with maintained benefits and an improved safety profile. This novel, highly potent development candidate is rapidly advancing toward clinical studies.
^{* Source: Anxiety and Depression Association of America}

Post-Traumatic Stress Disorder (PTSD):
5.7% of people age 13 and over will experience PTSD as some point in their lives.* Unfortunately, current therapies are restricted by inadequate efficacy and unwanted side effects. We are pursuing a first-in-class therapy for PTSD with sustainable treatment and safety benefits. Psy’s novel, highly potent development candidate is rapidly advancing towards an IND.
^{*Source: American Psychiatric Association}

Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD) is recognized as the leading cause of disability worldwide*.  While multiple treatment options are available, these therapies are restricted by significant tolerability issues, low response rate, adverse side effects and slow onset of action. Psy is advancing a potential best-in-class treatment for MDD with greater efficacy and an improved safety profile.
^{*Source: WHO, CDC}

Parkinson’s Disease (PD)
Over one million US adults suffer from PD*. While current therapies may provide temporary symptomatic relief, they fail to slow disease progression, are confounded by poor tolerability and can cause potentially fatal liver toxicity. Psy is advancing a potential best-in-class treatment for Parkinson’s with a meaningfully improved efficacy and safety profile.
^{*Source: Parkinson’s Foundation}

Alzheimer’s is the only top 10 leading cause of death in the United States that cannot be prevented, slowed down or cured.* Existing treatments may only offer temporary symptomatic benefit. Psy is pursuing a potential disease-modifying small-molecule therapeutic which would prevent the aggregation of tau proteins responsible for Alzheimer’s and related neurodegenerative disorders. Our potential first-in-class treatment is rapidly advancing through lead optimization.
^{*Source: Alzheimer’s Association}

All successfully screened